Top Markets
Coin of the day
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Peringkat dalam Saham #12750
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Harga Saham
$22.26
Terakhir disinkronkan: 2024-03-22
Kapitalisasi Pasar
$553.40M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Graphite Bio, Inc. (GRPH)

Kategori

Riwayat harga saham Graphite Bio, Inc. (GRPH)
Harga penutupan tertinggi: $23.07 pada 2024-03-01

Harga penutupan terendah: $174.18 pada 2021-06-01
Riwayat harga saham Graphite Bio, Inc. dari 2021 hingga 2026
Performa harga saham tahunan
Tahun Performa
2024 40.75%
2023 -26.18%
2022 -70.69%
2021 0.00%
Harga saham perusahaan atau pesaing serupa
Perusahaan Harga saham Perubahan 1th% Negara
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.01 -13.08%
AU
$138.18 473.58%
US
$750.94 6.02%
CH